Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest(™) 95GC Breast in a multi‑institutional registry study

Curebest™ 95GC breast (95GC) is a multigene classifier we developed for the prognostic prediction of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and node-negative (ER+/HER2-/n0) invasive breast cancer treated with adjuvant endocrine therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Naoi, Yasuto, Tsunashima, Ryo, Shimazu, Kenzo, Oikawa, Masahiro, Imanishi, Seiichi, Koyama, Hiroshi, Kamada, Yoshihiko, Ishihara, Kazuhiro, Suzuki, Masahiko, Osako, Tomo, Kinoshita, Takayuki, Suto, Akihiko, Nakamura, Seigo, Tsuda, Hitoshi, Noguchi, Shinzaburo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131261/
https://www.ncbi.nlm.nih.gov/pubmed/37123024
http://dx.doi.org/10.3892/ol.2023.13794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131261/
https://www.ncbi.nlm.nih.gov/pubmed/37123024
http://dx.doi.org/10.3892/ol.2023.13794

Ejemplares similares